Risk factors guide assessment, not a glaucoma diagnosis. The German screening intervals concern people without known glaucoma; manifest disease and diagnosed ocular hypertension need individual follow-up.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Define the clinical question and the evidence
Open-angle glaucoma involves progressive neuroretinal rim and retinal nerve fibre layer (RNFL) loss with corresponding visual-field damage. Early symptoms may be absent; risk assessment, detection, treatment and follow-up all contribute to care, so risk quantification is not the only means of preventing disability. 1 2
The DOG/BVA S2e update dated 3 March 2024 addresses adult risk and early detection, largely using populations of European ancestry; it does not set management for known glaucoma or diagnosed ocular hypertension. A strong A recommendation can coexist with evidence level 3 and expert consensus; Oxford 2011 levels and A/B/0 grades answer different questions. 2
The original reports advanced damage in about 1/3 and driving ineligibility in 10–20% at diagnosis. Those proportions require their populations, binocular-field criteria and jurisdiction; no individual driving decision follows from a diagnosis or these percentages alone. 1
02Keep incidence, prevalence and ancestry distinct
At age 40–80, the original summarises 5-year incidence as 0.5–1.5%, Rotterdam 0.6% over 5 years and northern Sweden 0.9% per year over 21 years. Different cohorts and observation periods cannot be combined into a personal annual risk. 1 2
Prevalence increases with age; the original 2.0–2.5-fold increase per decade from age 40 and 1.3-fold male prevalence are group associations, not individual forecasts. First-degree family history is associated with about 2.0–3.0-fold risk, but reporting and ascertainment affect the estimate. 1 2
The original approximately 3-fold estimate for darker-skinned populations and earlier onset, and rising risk with age in Latin American populations, need population-specific context. Skin colour is an imprecise proxy for ancestry and social factors; do not infer an individual genetic risk or a universal coefficient from appearance. 1 2
The lecture gives European glaucoma prevalence at age 40–80 as 2.93%, including 2.51% open-angle glaucoma. Its age examples are 0.4% at 40;2.7% at 70 and 10.0% at 90; definitions and population matter, and extrapolating beyond the sampled ages is unsafe. 1 2
03Interpret pressure and disc findings in context
Intraocular pressure (IOP) is the established treatment target, but high IOP is not synonymous with glaucoma. OHTS randomised 1636 selected patients aged 40–80 without glaucomatous damage, with IOP 24–32 mmHg in one eye and 21–32 in the other. At 60 months estimated glaucoma incidence was 9.5% with observation versus 4.4% with medication: HR 0.40, 95% CI 0.27–0.59. 1 3
The original 9% for every eye ≥24 mmHg overgeneralises and rounds the trial. Its 9.5% is a Kaplan–Meier estimate, not the raw 89/819=10.9% proportion; open treatment, masked endpoint assessment, attrition and allocation deviations matter. The CCT-adjustment study concerns risk prediction, not tonometer accuracy; central corneal thickness (CCT) does not justify a universal corrected-IOP formula. 3 4
Cup-to-disc ratio (CDR) ≥0.6 at an average-sized disc or inter-eye asymmetry ≥0.2 increases suspicion; the latter LR 3.9–4.1 is a diagnostic likelihood ratio, not a future-risk multiplier. Disc haemorrhage original 7.5-fold refers to prevalent association, not guaranteed progression; disc size, rim, fields and imaging must be assessed. 1 2
Myopia of magnitude ≥4 dioptres, conventionally ≤−4 D, and pseudoexfoliation (PEX) deserve closer assessment. Original estimates 2.3-fold for myopia and 4–6-fold for PEX depend on population and design and should not be multiplied together as an individual risk score. 1 2
The original myopia estimates are 2–3-fold from magnitude 4D and 1.5-fold per additional millimetre of axial length. These observational associations are neither additive nor a validated individual calculator. In pseudophakia, look for PEX beyond the absent natural anterior lens capsule: pupillary border, angle, deposits and prior records can help; “lens-periphery deposits only” is inadequate. 1 2
A vertical CDR≥0.6 in an average-sized disc has reported positive LR7.0–7.5; inter-eye difference≥0.3 has LR7.3. Neither a diagnostic LR nor a prevalent disc-haemorrhage association should be relabelled as future conversion probability. 1 2
04Ask about the route and preparation of steroids
Topical ocular, intravitreal and systemic steroids can raise IOP. The original up to 79% after 2.1 mg fluocinolone is a historical preparation- and definition-specific estimate; it does not describe every current implant, steroid response or glaucoma incidence. 1 2
The guideline discusses inhaled high doses, historically >4 puffs for at least 3 months, especially with family history. Different inhalers deliver different doses; this is not a safe no-risk threshold. Its intranasal review found no clinically important group increase, which does not prove zero individual risk or justify changing systemic treatment without coordination. 1 2
The original diabetes/hypertension associations of 1.16–1.4 require study-specific interpretation. Shared age and vascular factors, ascertainment and more frequent examinations can confound associations; neither condition proves a glaucomatous optic neuropathy. 1 2
The guideline discusses diabetes association 1.48 and hypertension 1.16, with inconsistent causality. Exploratory renal associations include uric-acid/creatinine ratio OR1.04 (95% CI1.01–1.07) and macroalbuminuria OR8.00 (2.97–21.5); a wide interval and observational design preclude treating these as established screening factors. 1 2
The historical intravitreal comparisons include pressure rise in 15% after dexamethasone 0.7 mg and 79% after fluocinolone 2.1 mg. These are different preparations, populations and definitions, not a head-to-head comparison or a current-dose recommendation. 1 2
05Offer screening with realistic expectations
DOG/BVA recommends offering screening from age 40, including binocular disc examination and IOP; recommendations 4-3 and 4-4 are strong but have evidence level 3. The historical 64% sensitivity/96% specificity estimate has selection/definition limits, including classifying IOP <18 mmHg as healthy; it is not universal test performance. 2
The Swedish screening follow-up reported blindness RR 0.52 over about 20 years after one screen at age 50–80. This observational follow-up is not the randomised EMGT treatment effect or proof that screening halves every individual risk. Discuss false positives, missed disease and the need to confirm a result. 1 2
A single IOP value cannot exclude OHT or glaucoma. The cited 5.3–6.9 mmHg between-day variation concerns a selected measurement series, not a universal instrument error. Suspicion leads to repeated IOP, perimetry, structural assessment, gonioscopy and pachymetry as appropriate before a treatment decision. 1 2
The lecture’s tonometry sensitivity about 30% at a cutoff>21mmHg and combined specificity 96% concern different test definitions and selected studies. They do not give one universal sensitivity/specificity pair; morphology, field, imaging and clinical context are needed. 1 2
06Use intervals as consensus guidance, then confirm the diagnosis
The interval table preserves the four original risk groups. These are 2024 German expert-consensus screening intervals after excluding glaucoma, not a schedule for symptomatic patients or established disease. Relevant additional factors include first-degree family history, myopia magnitude ≥4 D, ancestry context, IOP 22–25 mmHg interpreted with CCT, borderline CDR/asymmetry and prolonged ocular/systemic steroids. 2
The original quick-review A/B labels are retained as export labels, not certified as separate recommendations for each association. The guideline bases intervals on combined risk and age; men do not receive a different interval solely because their average prevalence is higher. Explain a positive screen, confirm or exclude disease, document the next visit and individualise when necessary. 1 2
The inspected 2024 consensus also considers screening from age 30 in the guideline’s darker-skinned population category. Below 40, it gives 5 years with 1 factor,2–3 years with 2 factors and yearly with≥3. These consensus intervals are distinct from follow-up of known glaucoma or diagnosed ocular hypertension. 2
| Risk factor | Estimate and limit | Original Oxford 2011 LoE | Next step |
|---|---|---|---|
| Age per decade | 2.0–2.5-fold prevalence | 1 | Screen from 40 using overall risk, not individual prediction |
| IOP≥24mmHg | 9.5% over 5 years in selected untreated OHTS participants | 1 | Individual OHT assessment; not the risk of every high-pressure eye |
| First-degree family history | 2–3-fold association | 2 | Shorter interval according to age and combined risk |
| Pseudoexfoliation (PEX) | 4–6-fold association | 2 | At least yearly screening; examine relevant anterior structures |
| Myopia magnitude≥4D (usually≤−4D) | 2–3-fold association | 2 | Shorten interval to 2–3 years or 1 year according to age and risk |
| Inter-eye CDR difference≥0.2 | Positive LR about 4.0 | 1 | Confirm suspicious morphology; LR is not future risk |
| Disc-margin haemorrhage | Original 7.5-fold prevalent association | 2 | Investigate glaucoma and alternatives; not proof of progression |
| Ancestry context, original darker skin | Original 3-fold group association | 1 | Consider screening from 30; consensus, not individual genetic coefficient |
| Ocular/systemic steroids | Pressure-rise risk depends on route, dose and preparation | 2 | Review medication and monitor IOP without abrupt uncoordinated withdrawal |
What are the main learning points?
Risk factors guide assessment, not a glaucoma diagnosis. The German screening intervals concern people without known glaucoma; manifest disease and diagnosed ocular hypertension need individual follow-up.
When is assessment urgent?
Sudden visual loss, severe eye pain, new field loss or marked pressure elevation needs prompt assessment rather than waiting for the next screening date.
References and access status
- 1Immutable original export; S2e risk and early-detection lecture; examiner role unverified
Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2DOG/BVA S2e 045-015, 3 March 2024
Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Selected extracted original PDF text read 15 November 2026: scope p1, incidence table p8, selected PEX/prevalence p13–14, steroids and disc findings p16–18, recommendations and intervals p19–27. Not the complete 34-page report or all cited studies; source table layout needs image confirmation.
- 3OHTS 2002; PMID 12049574
Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Historical full-text appraisal from review 005 on 2–6 October 2026 and Issue 161 notes reused; not newly read. Open treatment and masked endpoint assessment distinguished.
- 4Brandt et al. CCT-adjusted IOP and OHTS prediction. 2012; PMID 21705084
Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Historical review 005 full-text appraisal reused, with complete-case and delayed-CCT limits. Risk-model discrimination is not measurement accuracy; no new full-text claim.
- 5Immutable original export; WBO risk/screening export; examiner identity not verified
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
Original lecture link
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
- Original lecture link; recording unchecked
For patients
Glaucoma can damage the optic nerve before you notice symptoms. An abnormal screening test leads to further tests; it does not automatically mean you have glaucoma.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, severe eye pain, new field loss or marked pressure elevation needs prompt assessment rather than waiting for the next screening date.
Sudden visual loss, severe eye pain, new field loss or marked pressure elevation needs prompt assessment rather than waiting for the next screening date.